Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory (R/R) regimens. In first-line therapy, the synergy between ICIs and chemotherapy may surpass the previous standards of AB...

Full description

Bibliographic Details
Main Authors: Charles J. Milrod, Ari Pelcovits, Thomas A. Ollila
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
Hodgkin lymphoma
immune checkpoint inhibitors
biomarkers
survival endpoints
clinical trials
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1397053/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1397053/full

Similar Items